Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine in ADHD and Comorbid Dyslexia
NCT00191048Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), sponsored by Eli Lilly and Company. Primary endpoint: ADHD Rating Scale-IV-Parent:Investigator-Administered and Scored at 16 weeks. Started Oct 2003; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00191048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191048.